| Not Yet Recruiting | Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopath NCT05094011 | Taiwan Mitochondrion Applied Technology Co., Ltd. | Phase 1 |
| Recruiting | A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's NCT07106021 | Kenai Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disea NCT05931575 | Technical University of Munich | Phase 2 |
| Unknown | Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson's Disease NCT05691114 | Shanghai East Hospital | Phase 1 |
| Completed | Fatigue, Sleep and Quality of Life in Parkinson's Patients NCT05687799 | Nigde Omer Halisdemir University | — |
| Completed | Comparison of Balance, Activity-specific Balance Confidence and Quality of Life in Parkinson's Patients NCT05671341 | Nigde Omer Halisdemir University | — |
| Completed | Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing NCT05107531 | Hacettepe University | — |
| Completed | Dopamine Effect on Inhibitory Control NCT03665493 | Giovanni Mirabella | N/A |
| Completed | The Acute Effect of Cervical Mobilization in Parkinson's Disease NCT04524143 | Hacettepe University | N/A |
| Completed | The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease NCT04524182 | Hacettepe University | N/A |
| Completed | Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease NCT03065192 | Neurocrine Biosciences | Phase 1 |
| Unknown | PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease NCT02801110 | david groshar | — |
| Completed | Sleep, Awake & Move - Part II NCT02710487 | Neurocenter of Southern Switzerland | N/A |
| Terminated | Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy NCT02525367 | Amsterdam UMC, location VUmc | N/A |
| Suspended | Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stim NCT03074812 | Johns Hopkins University | N/A |
| Completed | Volumetric Bone Mineral Density and it's Relationship With Osteoporotic Fractures in Parkinson's Disease NCT03095690 | Centre Hospitalier Régional d'Orléans | N/A |
| Completed | Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease NCT02610231 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Completed | PF-06669571 In Subjects With Idiopathic Parkinson's Disease NCT02565628 | Pfizer | Phase 1 |
| Completed | PA Behavior and HRQoL in Parkinson's Disease Patients Patients: Role of Social Cognitive Variables NCT05575479 | Ohio State University | — |
| Terminated | Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients NCT02453386 | Biotie Therapies Inc. | Phase 3 |
| Completed | Randomized Safety Study of CVT-301 Compared to an Observational Control Group NCT02352363 | Acorda Therapeutics | Phase 3 |
| Completed | Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes NCT02242487 | Acorda Therapeutics | Phase 3 |
| Active Not Recruiting | Infusion of Apomorphine: Long-term Safety Study NCT02339064 | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | Phase 3 |
| Unknown | Whole-body Vibration as a Treatment for Parkinson's Disease NCT02306863 | Sun Life Financial Movement Disorders Research and Rehabilitation Centre | N/A |
| Completed | Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes NCT02240030 | Acorda Therapeutics | Phase 3 |
| Completed | Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson NCT02227355 | UCB Biopharma S.P.R.L. | — |
| Unknown | Vascular Abnormalities in Idiopathic Parkinson's Disease NCT02045420 | University of Saskatchewan | — |
| Completed | A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Dis NCT01968031 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Terminated | Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease and Progre NCT01815281 | IRCCS San Raffaele Roma | N/A |
| Completed | Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes NCT01777555 | Acorda Therapeutics | Phase 2 |
| Terminated | Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease NCT01789047 | Rush University Medical Center | Phase 2 |
| Completed | Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy NCT01782222 | UCB BIOSCIENCES GmbH | Phase 4 |
| Completed | Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease NCT01970813 | Kyunghee University Medical Center | N/A |
| Completed | Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's NCT01646268 | UCB Pharma | Phase 3 |
| Completed | Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease P NCT01646255 | UCB Pharma | Phase 3 |
| Completed | Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Dise NCT01606670 | UCB Pharma GmbH | — |
| Completed | Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes NCT01617135 | Acorda Therapeutics | Phase 2 |
| Completed | Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Pa NCT01523301 | UCB Korea Co., Ltd. | Phase 4 |
| Completed | Robot Walking Rehabilitation in Parkinson's Disease NCT01668407 | IRCCS San Raffaele Roma | N/A |
| Completed | The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease NCT01470859 | Huashan Hospital | N/A |
| Completed | Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregive NCT01330290 | UCB Pharma | — |
| Completed | Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-moto NCT01300819 | UCB Pharma | Phase 4 |
| Completed | Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) NCT01227265 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Vercise Implantable Stimulator for Treating Parkinson's Disease NCT01221948 | Boston Scientific Corporation | Phase 2 |
| Completed | Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transder NCT01159691 | UCB Pharma GmbH | — |
| Completed | Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Com NCT01007864 | Desitin Arzneimittel GmbH | Phase 3 |
| Completed | Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease NCT00985517 | Sangamo Therapeutics | Phase 1 / Phase 2 |
| Terminated | MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of NCT01028586 | Newron Pharmaceuticals SPA | Phase 3 |
| Completed | A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics NCT01026428 | Newron Pharmaceuticals SPA | Phase 1 / Phase 2 |
| Completed | Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa NCT00627640 | Newron Pharmaceuticals SPA | Phase 3 |
| Completed | Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease NCT00873392 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Terminated | Impact of Deep Brain Stimulation of Subthalamic Nucleus on the Hepatic Glucose Production in Parkinson's Disea NCT00663312 | University Hospital, Clermont-Ferrand | N/A |
| Completed | MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist NCT00605683 | Newron Pharmaceuticals SPA | Phase 3 |
| Completed | Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact NCT00664157 | University Hospital, Clermont-Ferrand | N/A |
| Unknown | The APOS System: Effects on Gait, Mobility and QOL in Patients With Parkinson's Disease NCT00498758 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Completed | The Effectiveness of Biofeedback Treatment in Constipated Patients With Idiopathic Parkinson's Disease NCT00869830 | Asan Medical Center | N/A |
| Completed | Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's D NCT00400634 | Sangamo Therapeutics | Phase 2 |
| Completed | Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease NCT00279825 | Impax Laboratories, LLC | Phase 2 |
| Completed | Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease NCT00239564 | Impax Laboratories, LLC | Phase 1 / Phase 2 |
| Completed | Stalevo in Early Wearing-Off Patients NCT00125567 | Orion Corporation, Orion Pharma | Phase 4 |
| Completed | A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treat NCT00148369 | Amgen | — |
| Terminated | Walking Capacity in Parkinson's Disease (PD-Walk) NCT00261781 | Natalie Allen | N/A |
| Completed | An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Su NCT00505687 | UCB Pharma | Phase 3 |
| Completed | A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Di NCT00243945 | UCB Pharma | Phase 3 |
| Completed | Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose NCT00643045 | Newron Pharmaceuticals SPA | Phase 3 |
| Completed | Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idio NCT00115427 | Amgen | Phase 1 |